Laser and eye drop combo may offer new hope for baby tumors
NCT ID NCT07560332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compared two treatments for infantile hemangioma, a common benign tumor in children. One group received oral propranolol daily for 3 months, while the other had weekly fractional CO2 laser sessions followed by topical timolol drops. The trial enrolled 30 children aged 1 month to 12 years and measured improvement using a global assessment score. The goal was to see if the laser-and-drop approach works as well as the oral medication.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- propranolol (oral) and timolol (topical)
- What this could lead to
- If successful, this could show that laser-assisted topical timolol is as effective as oral propranolol, offering a less invasive treatment option for infantile hemangioma.
- What could go wrong
- This is a small, completed trial with only 30 participants, so results may not apply broadly. Both treatments have known side effects, and the laser procedure may cause discomfort or scarring.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INFANTILE HEMANGIOMA (IH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cairo University
Cairo, 11562, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.